This message contains images. If you don't see images, click here to view.
Advertise in this news brief.




Text Version    RSS    Subscribe    Unsubscribe    Archive    Media Kit           August 19, 2015

Home     About SGO    Education    Membership    Clinical Practice    Public Policy    Blog    Partnerships    Store

 

HPV vaccine mandate in Rhode Island won't change, health officials say
The Associated Press via Business Insider
State health officials say there are no plans to change a new requirement that middle school students in Rhode Island get the HPV vaccine even though some parents, and now some lawmakers, have expressed concerns. Children entering seventh grade in September must get the vaccine unless their parents seek an exemption for medical or religious reasons. Virginia and Washington, D.C., are the only other jurisdictions that require the vaccine to attend school.
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE  




SGO NEWS


Annual Meeting Call for Abstracts and Surgical Films deadline: Sept. 15
The Call for Abstracts and Surgical Films for the 2016 SGO Annual Meeting on Women’s Cancer is now open and closes at 11:59 p.m. CT Tuesday, Sept. 15. The 47th Annual Meeting will take place March 19-22, 2016, at the San Diego Convention Center in San Diego, CA.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


CERVICAL CANCER


Low hanging fruit: Cervical cancer and how the US is falling behind
Forbes
In the United States, our health system is far from perfect, but we like to pride ourselves on delivering the highest quality and newest innovations in care. But one area where we lag behind even some African nations is in preventing cervical cancer — the most common gynecologic cancer worldwide. In Rwanda for example, as breast and cervical cancer rates began to rise in 2010, Rwanda’s Minister of Health, Dr. Agnes Binagwaho, quickly responded by launching a national campaign to vaccinate schoolgirls against HPV — the human papilloma virus that causes nearly all cases of cervical cancer.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Advertisement
SPONSORED CONTENT


GENETICS


RAD51 mutations confer moderate risk of ovarian cancer
HealthDay News via Doctors Lounge
Deleterious mutations in RAD51C and RAD51D genes are associated with increased risk of epithelial ovarian cancer (EOC), according to a study published online Aug. 10 in the Journal of Clinical Oncology. Honglin Song, PhD, from the University of Cambridge in the United Kingdom, and colleagues conducted a genetic study using germline DNA from 3,429 patients with invasive EOC and 2,772 controls from a case-control study, as well as 2,000 unaffected BRCA1/2-negative women from the U.K. Familial Ovarian Cancer Screening Study.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Broader BRCA mutation gene test may help some
HealthDay News via WebMD
Some women with a family history of breast or ovarian cancer might benefit from a broader genetic test that includes more than 20 genes that have been found to increase cancer risk, a new study published in JAMA Oncology suggests. Genetic tests have tended to focus solely on BRCA1 and BRCA2, the two genetic mutations that have been proven to dramatically increase a woman's risk for breast or ovarian cancer, the researchers said.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Advertisement
PRODUCT SHOWCASE
  ChemoFx Improves Ovarian Cancer Outcomes
ChemoFx® provides invaluable information to physicians choosing from 20+ equivalent treatment recommendations without prior knowledge of how individual patients may respond. ChemoFx determines platinum resistance in primary ovarian cancer and demonstrates longer overall survival by 14 months in recurrent ovarian cancer, making it instrumental in improving patient outcomes.
 


BREAST CANCER


Ovarian function protected in some breast cancer patients with GnRH agonist
Clinical Oncology
Administering a gonadotropin-releasing hormone (GnRH) agonist to women with hormone receptor–negative breast cancer protects the ovaries, a clinical trial confirms — adding to evidence from earlier reports. Prior studies provide mixed results related to the effect of GnRH agonists on patients with estrogen receptor — positive breast cancer, as well as those receiving treatment subsequent to rather than concurrent with chemotherapy.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


  Ovarian cancer updates from ASCO 2015:

Four prominent experts in ovarian cancer met in Chicago to provide perspectives related to progress made toward personalized therapy. More
 


LYNCH SYNDROME


Daily aspirin dose draws back obesity-related cancer risks — study
RT
Simple aspirin could be a powerful weapon for overweight people to reduce any additional risks of developing colon cancer stemming from a genetic predisposition called Lynch syndrome, a new international study has revealed. The decade-long study, published in the Journal of Clinical Oncology, revealed that being overweight more than doubles the risk of developing cancer in patients with Lynch syndrome.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE




CLINICAL TRIALS


Clinical cancer trials failing the elderly population
Medscape Oncology
When an elderly patient is treated with a cancer drug, it is very likely that the drug has not been tested in a patient who is similar to them. "Cancer clinical trials have been conducted primarily in middle aged patients, 50-60 years of age, 10-15 years younger than the incidence of the disease in the population," said Stuart Lichtman, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center in New York City. "We know that 60 percent of cancer is in people over the age of 65, and 79 percent of cancer mortality is in people greater than 65 years of age. We treat older patients, particularly over the age of 80, with no evidence base whatsoever." During a presentation at the annual meeting of the American Society of Clinical Oncology (ASCO), Dr Lichtman said that changes are needed to the clinical trials infrastructure to improve cancer care for the elderly.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


MISSED AN ISSUE OF WOMEN'S CANCER NEWS?
Visit the SGO Women's Cancer News archive page.


 



Women's Cancer News
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Jessica Taylor, Senior Medical Editor, 202-684-7169  
Contribute news


Inclusion of advertisements does not constitute SGO endorsement of company products or services.

Be sure to add us to your address book or safe sender list so our emails get to your inbox. Learn how.

This edition of the Women's Cancer News was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!

Recent issues

Aug. 12, 2015
Aug. 5, 2015
July 29, 2015
July 22, 2015






7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063